DrugPatentWatch Database Preview

Details for Patent: 8,007,830

« Back to Dashboard

Which drugs does patent 8,007,830 protect, and when does it expire?

Patent 8,007,830 protects SINGULAIR and is included in one NDA.

This patent has twenty-eight patent family members in twenty-five countries.

Summary for Patent: 8,007,830

Title:	Granule formation
Abstract:	The present invention relates to oral granules of montelukast sodium.
Inventor(s):	Down; Brian (Pierrefonds, CA)
Assignee:	Merck Frosst Canada & Co. (Quebec, CA)
Application Number:	12/069,124
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,007,830
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 8,007,830
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound;

Drugs Protected by US Patent 8,007,830

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck	SINGULAIR	montelukast sodium	GRANULE;ORAL	021409-001	Jul 26, 2002	AB	RX	Yes	Yes			Y

International Family Members for US Patent 8,007,830

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	385781
Australia	2002333134
Brazil	0213477
Canada	2463947